1 2012-Annual Report Name of the Department: Name of the Structure: Direction Médicale Pôle Intégré de Recherche Clinique (PIRC) Secondary Affiliation: - Head of the laboratory: Dr Cécile Delval, Personnel: Personnel Cécile Artaud Olivia Chény Isaure de la Croix Margaux Dewitte Annick Dubois Nathalie Jolly Emmanuelle Laffly Hélène Lafolly Camille Pitrou Position Preclinical Clinical study coordinator Secretary Trainee Trainee Preclinical Research Coordinator Five Main publications (in years ): NON APPLICABLE Website address of your laboratory: Key-words of the annual report: Preclinical research Vaccine candidates Gene Therapy Clinical research Regulatory authorities Sponsor Ethic
2 2012-Annual Report I. Presentation The Pôle Intégré de Recherche Clinique (PIRC), created in January 2008: - represents the Institut Pasteur when sponsor, - ensures the coordination of the internal Institut Pasteur Clinical Research Committee (CoRC), - supports scientists for the preparation of clinical research projects before and after submission to the CORC, - is responsible for submission to competent regulatory authorities prior to the beginning of the research, - coordinates the conduct of the research in accordance with the Good Clinical Practices, - ensures all clinical research development steps including budget plan and follow up, - ensures the coordination of the development of the Institut Pasteur vaccine candidates/drugs/gene therapy (preclinical and clinical phases I/II), - ensures a quality assurance system and safety monitoring, - ensures a training course at Institut Pasteur (Recherche sur la Personne et Ethique Appliquée, Research on Human Beings and Applied Ethics, RPEA). II. Activities II. A. Preclinical Research In 2012, the PIRC was involved in two major vaccine development programs (MagTn3, Anthrax), two European FP7 Consortia (STOPENTERICS, ANTIFLU) and one Advanced Therapy project concerning gene therapy for Sanfilippo type B disease. MagTn3: development of a therapeutic anti-cancer vaccine targeting adeno-carcinomaassociated Tn carbohydrate antigen capable of inducing tumor-specific antibodies. Preclinical batches were produced. Toxicology studies and manufacturing of the clinical batches have started and are still on going. Collaboration with C. Leclerc, R. Lo-Man (Unité de Régulation immunitaire et vaccinologie) and S. Bay (Unité de Chimie des biomolécules). Mucopolysaccharidosis (MPS) type III: development of a gene therapy consisting of the intracranial injection of an Adeno-Associated Virus vector coding for the a-n-glucosaminidase, the deficient enzyme in the Sanfilippo type B patient. The PIRC was involved in the coordination of preclinical activities including manufacturing of clinical batches, management of the regulatory toxicology/biodistribution studies, and preparation of all required documentation for clinical trial authorization submission. Collaboration with J.-M. Heard (Département de Neuroscience). Anthrax: development of a therapeutic vaccine for the army force in case of high-risk exposure. The manufacturing of the FIS and rpa development batches and the analytical method development by the subcontractor in charge of the vaccine candidate manufacturing have started and are still on going. Collaboration with P. Goossens (Laboratoire Pathogénie des toxi-infections bactériennes). STOPENTERICS FP7 Consortium: development of a novel prophylactic vaccine against Shigella. As the PIRC is involved as sponsor representative of the phase I clinical trial, the PIRC has participated in the annual consortium meeting. The PIRC was also involved in the coordination of preclinical activities including manufacturing of the starting material for the preclinical and clinical batches of the vaccine candidate. Collaboration with P. Sansonetti, FP7 coordinator, and A. Phalipon (Unité de Pathogénie microbienne moléculaire) and L. Mulard (Unité de Chimie des biomolécules). ANTIFLU FP7 Consortium: development of new and alternative drugs against influenza by exploiting the crucial function of host cell determinants as targets of small molecules and RNAi inhibitors, so-called indirect antiviral targets, in order to prevent viral infection and growth. The PIRC has participated in the annual consortium meeting and will be involved in the coordination of the preclinical activities. Collaboration with M. Lecuit (Groupe à 5 ans Microorganismes et barrières de l'hôte) and T. Meyer (the Max Planck Institute for Infection Biology, FP7 Coordinator).
3 II.B. The clinical research activities The role of the PIRC is to ensure the representation of Institut Pasteur when sponsor. Its duty is to bridge laboratory-based research with patient-oriented clinical research. Scope of activities of the PIRC: Clinical research = any research involving human beings: biological samples and/or personal data and/or physiopathology and/or epidemiology, and/or clinical trials In 2012: 186 projects were piloted by the PIRC since new clinical research projects were reviewed by the Clinical Research Committee (CoRC) according to regulatory, legal and ethical compliance. The Institut Pasteur was sponsor/legal responsible for 29/46 projects (63%) of these projects. 11/46 projects (24%) were conducted in collaboration with Institut Pasteur International Network. Repartition of Institut Pasteur sponsorship of research projects (n=178) Major studies piloted by the PIRC, completed in 2011 (IP sponsor): BCG & bladder cancer: Objective: to analyze predictive factors for success of BCG therapy in bladder cancer. Collaboration with M. Albert (Centre d Immunologie Humaine). RMV HIV: Objective: to test a HIV vaccine based on a recombinant Measles vaccine vector. This Phase I clinical trial is an open-label, single-centre dose-escalation study on healthy subjects. Results were analyzed and study report was completed. Publication is in progress and publically registered on Belgian Competent Authorities data base. Collaboration with F. Tangy (Unité de Génomique virale et vaccination).
4 Major studies piloted by the PIRC (IP sponsor), still in progress: Chronovac: Objective: to evaluate immune response of the administration of 2 vaccines against yellow fever and measles in young children. Start of volunteers recruitment in February 2011; current status (Dec. 2012) : 97 included/124 planned. Collaboration with C. Goujon (Centre Médical de l Institut Pasteur, clinical investigator) and M.-L. Gougeon (Unité de Recherche et d Expertise Immunité anti-virale). METHS: Objective: to identify causes of Verneuil disease. Collaboration with A. Nassif (Centre Médical de l Institut Pasteur, clinical investigator) and O. Joint-Lambert (Laboratoire de Microbiologie, Hôpital Necker, Paris). Start of volunteers recruitment in November 2011 ; current status (Dec. 2012) : 35 included/75 planned. LabEx Milieu Intérieur Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine : Objective: constitution of a large healthy volunteers cohort to define the determinants of human immune variance. Start of volunteers recruitment in September 2012; current status (Dec. 2012): 261 included/1000 planned. Collaboration with M. Albert (Centre d'immunologie Humaine) and L. Quintana-Murci (Unité Génétique évolutive humaine). INECOC: Objective: to detect and characterize the presence of infectious agent transcripts in oncology. Start of volunteers recruitment in February 2012; current status (Dec. 2012): 15 included/100 planned). Collaboration with A. Gessain (Unité d'epidémiologie et physiopathologie des virus oncogènes). EVOIMMUNOPOP: Objective: to characterize the genetic architecture of populations with different ethnic backgrounds. Start of volunteers recruitment in December 2012 ; current status (Dec. 2012) : 31 included/400 planned. Collaboration with L. Quintana-Murci (Unité Génétique évolutive humaine). II.C. European Ethical Process In 2012, the PIRC was fully involved in the preparation of Applications for EU Grant in order to support scientists in the implementation of the Regulatory & Ethical considerations. II.D. PIRC as a regulatory-ethical referent The PIRC was solicited to contribute to the implementation of the non-opposition procedures for collections of human biological samples stored by the CNRs. In order to support scientists in their publication, the PIRC has deeply reviewed the guidelines of the International Committee of Medical Journal Editors (ICMJE) and implemented specific recommendations for scientists. II.E. Teaching / communication Bimonthly workshops Ateliers du PIRC Objective: to clarify scientific, regulatory and ethic aspects of the clinical research environment. Started in 2010, this initiative was largely successful and was renewed in Training Course «Recherche sur la Personne et Ethique Appliquée / Research on Human Beings and Applied Ethics» (RPEA) Objective: to clarify the rules of the research on human beings with a particular focus on ethics. For the fourth consecutive year, this course has trained students with previous experience in clinical research to the regulatory aspects of research on the person.
5 Training Course «Clinical Research in the Institut Pasteur International Network ( CREPIN ) In 2012, PIRC has been requested by the International Division to build up a new course on Clinical Research dedicated to the International Network. The first session will teach students from Asia; it will take place in Cambodia in April PIRC web site In 2012, the PIRC set up a new web site
- AIRC - Associazione Italiana per la Ricerca sul Cancro CALL FOR PROPOSALS 2015 My First AIRC Grant (MFAG) AIRC Via San Vito 7, 20123 Milano tel. 02/7797374-222-350 fax 02/7797259 e-mail: email@example.com
European Medicines Agency London, 30 May 2008 Doc. Ref. EMEA/CHMP/GTWP/60436/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON FOLLOW-UP OF PATIENTS ADMINISTERED WITH GENE THERAPY
FDA Report FDA ACTION PLAN TO ENHANCE THE COLLECTION AND AVAILABILITY OF DEMOGRAPHIC SUBGROUP DATA August 2014 Table of Contents Introduction and Background... 1 FDA Action Plan to Enhance the Collection
Section des Unités de recherche AERES report on the research unit Génomique, bioinformatique et applications From the Conservatoire National des Arts et Métiers (CNAM) Mai 2010 Section des Unités de recherche
Understanding the Clinical Research Process and Principles of Clinical Research Participant Guide Name INTRODUCTION... 1 What Is AIDS?...1 What Is the History of AIDS?...2 What Are the Division of AIDS
This report presents the recommendations of a WHO expert committee commissioned to coordinate activities leading to the adoption of international recommendations for the production and control of vaccines
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
10 June 2014 CANCER CONTROL STRATEGY FOR POLAND 2015-2024 Project Coordinator Office of the Project we should think big, act small, dare to fail, stop talking and start acting NOW Lucien Engelen 3 4 Contents
Code of Good Scientific Practice Research centres Hospital del Mar Medical Research Institute www.imim.es Dept. of Experimental and Health Sciences of the UPF www.upf.edu/cexs Centre for Genomic Regulation
MEDICAL / CLINICAL PSYCHOLOGY GRADUATE PROGRAM Policies, Guidelines, and Procedures The University of Alabama at Birmingham April 1, 2015 Table of Contents Program Mission Statement... 1 This Handbook...
NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA MARCH 2015 Table of Contents Executive Summary................................ 2 Introduction................................... 4 Goals
III Edition May 2013 - November 2014 Siena, Italy Master Program in Vaccinology and Pharmaceutical Clinical Development University of Siena Medical School Index Sponsors 3 Technical-Scientific Committee
Nursing Education Programs and Licensure Requirements General Nursing Education Programs and Licensure Requirements General General 20-90-45. Definition of terms As used in sections 20-90-45 to sections
ACCREDITATION COUNCIL FOR PHARMACY EDUCATION ACCREDITATION STANDARDS AND GUIDELINES FOR THE PROFESSIONAL PROGRAM IN PHARMACY LEADING TO THE DOCTOR RELEASED: FEBRUARY 17, 2006 EFFECTIVE: JULY 1, 2007 Accreditation
UCL RESEARCH DEPARTMENT OF EPIDEMIOLOGY AND PUBLIC HEALTH Institute of Epidemiology and Health Care RESEARCH ASSISTANT (DATA ANALYST / STATISTICIAN) THE CALIBER PROGRAMME Applications are invited for this
Response of the German Medical Association to the European Commission proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and
MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR
Section des Unités de recherche Report from the visiting committee Research unit : Therapy of striated muscles disorders University of Paris 6 April 2008 Section des Unités de recherche Report from the
Agency #067.00 CHAPTER SIX STANDARDS FOR NURSING EDUCATION PROGRAMS SECTION I APPROVAL OF PROGRAMS This chapter presents the Standards established by the Arkansas State Board of Nursing for nursing education
Rare Diseases: Common Issues in Drug Development Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
Guidelines for Animal Disease Control 1. Introduction and objectives The guidelines are intended to help countries identify priorities, objectives and the desired goal of disease control programmes. Disease
Statutory financial statements at Approved by the Shareholders Meeting of 23 April 2012 English translation for convenience MolMed S.p.A. is a biotechnology company focused on research, development and
Australian Medical Council Limited Procedures for Assessment and Accreditation of Medical Schools by the Australian Medical Council 2011 Medical School Accreditation Committee These procedures were approved